What are the NCCN recommendations for management of non-clear cell stage IV renal cell cancer (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

For patients with non–clear cell histology, NCCN recommendations for systemic therapy include the following:

  • Clinical trial (preferred)
  • Sunitinib (preferred)
  • Axitinib
  • Bevacizumab
  • Bevacizumab + erlotinib for selected patients with advanced papillary RCC, including hereditary leiomyomatosis–associated RCC (HLRCC)
  • Bevacizumab + everolimus for selected patients with advanced papillary RCC including HLRCC
  • Cabozantinib
  • Erlotinib
  • Everolimus
  • Lenvatinib + everolimus
  • Nivolumab
  • Pazopanib
  • Sorafenib
  • Temsirolimus (category 1 for poor-prognosis patients;hcategory 2A for other risk groups)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!